CTOs on the Move


 
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.imv-inc.com
  • 130 Eileen Stubbs Ave
    Dartmouth, NS CAN B3B 2C4
  • Phone: 902.492.1819

Executives

Name Title Contact Details

Funding

IMV raised $29.5M on 03/11/2019
IMV raised $25.1M on 05/18/2020

Similar Companies

BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.

Capital Royalty L.P.

Capital Royalty L.P. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

CAMP4 Therapeutics

What if we told you that our bodies make use of only a few hundred different signaling pathways to control all of our 20,000 or so genes. We call it the gene circuitry code, unique for every gene in our body. CAMP4 has built a proprietary 4-D Gene Circuity Platform to codify the discrete set of combinatorial rules used by any human cell type central to disease pathology. By applying the power of computational biology and machine learning algorithms, CAMP4 is able to rapidly solve for druggable targets to control the output of any disease gene of interest.

Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world`s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient`s journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

GentiBio

GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases.